Protocol Ledger

NCT05998642 · Phase II · RECRUITING

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Interventional Phase II clinical trial protocol NCT05998642 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-13 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05998642
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05998642
Protocol FieldVerified Registry Value
NCT IdentifierNCT05998642
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2024-02-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05998642
Hospital Research SiteLocationSite Profile
Arthur J E Child Comprehensive Cancer CentreCalgary, CanadaOpen Hospital Dossier ->
University Health NetworkToronto, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI